植物制成口服乙肝疫苗

StephenW

http://www.medicalnewstoday.com/articles/221274.php
PlantPharm Biomed On Target To Introduce First Plant-Based Hepatitis B Vaccine05 Apr 2011   

PlantPharm Biomed, a leader in plant-derived biomanufacturing, is on the cusp of introducing one of the first Plant-Made Pharmaceuticals (PMPs) with the release of an oral Hepatitis B vaccine proven to work in human subjects in a double-blind, placebo controlled Phase I clinical trial. The company is currently seeking FDA approval of the product, with other Plant-Made Pharmaceuticals products to follow.

Plant-Made Pharmaceuticals offer a faster, lower cost, more efficient method of producing pharmaceuticals, however, the industry has been struggling for years to find a method of production that is safe and effective. To achieve success, pharmaceutical proteins in plants must be grown in a zero-tolerance, 100% containment method for the public safety, with no potential to co-mingle with the food or seed supply. PlantPharm Biomed developed a proprietary, closed-environment growing system that has been perfected in cooperation with NASA. This biomanufacturing technology includes 30 patents and registrations worldwide, and the controlled environment production of fast growth, pathogen-free seed potatoes has been perfected by the company for more than a decade. PlantPharm is pleased to announce that the technology is now ready for use in biomanufacturing Plant-Made Pharmaceuticals.

Recognized with Current Good Manufacturing Practices (cGMP) certification and supported the US National Institutes of Health (NIH), PlantPharm's technology is designed to control all plant growth needs in a completely closed production system that is computer-controlled to provide for as many as six crops annually. Plants are grown with precise duplication of conditions to provide for optimum production for each harvest, and with full containment security for prevention of plant genetic migration into the wild.

PlantPharm Biomed is on track to be the first-to-market with an oral dose hepatitis B vaccine produced completely in potato plants. The global demand is evident for a low-cost, shelf-stable, orally administered vaccine. According to the World Health Organization (WHO), goals to reduce hepatitis B infections by 2012 are at risk due to immunization and surveillance gaps. Nearly 2 billion people are infected with hepatitis B, and 350 million more have chronic infections. With PlantPharm's patented technology, cost of production for a hepatitis B vaccine will reduce the per dose costs to recipients by nearly 50%. The dosage is also oral rather than injected, making it is easier to administer in mass quantities with a greater shelf life than liquid vaccines, a particular problem in places with inadequate refrigeration and infrastructure limitations, such as in third-world countries.

Source:
PlantPharm Biomed

StephenW

PlantPharm生物医学，在植物源生物制造的领导者，在引进的第一家工厂，作出的药品器（PMP）与B型肝炎的口服证明在人体中工作的双盲，安慰剂疫苗释放一个风口浪尖控制的一期临床试验。该公司目前正在寻求与其它植物制成的药物产品，美国FDA批准的产品，遵循。

植物制成药品提供了更快，成本更低，更有效的药品生产方法，然而，该行业多年来一直在努力寻找一种生产方法是安全有效的。为了取得成功，必须在植物药物蛋白生长在一个零容忍，100％的公众安全控制方法，并没有潜在的合作与食物混合或种子供应。 PlantPharm生物医学开发出一种专利，封闭环境中的成长系统，已与美国航天局合作，完善。这种生物制造技术包括全球30项专利和注册，和快速增长的受控环境中生产，无病原体种薯已经完善了公司超过十年。 PlantPharm很高兴地宣布，该技术现在已经投入使用的生物制造植物制成药品。

与现行良好制造规范（cGMP）的认证，认可并支持美国国立卫生研究院（NIH），PlantPharm的技术是用于控制所有植物生长在一个完全封闭的生产系统，电脑控制，提供多达六个需要每年农作物。植物生长与条件的精确复制，提供为每个收获最佳生产，并为预防植物遗传迁移到野生全密封安全。

PlantPharm生物医学上了轨道与一个口服剂量乙肝疫苗率先向市场生产的马铃薯完全。全球需求是显而易见的，低成本，耐贮存，口服疫苗。据世界卫生组织（卫生组织），2012年目标，以减少感染乙肝的风险是由于免疫和监测的空白。近20亿人感染乙型肝炎，和350多万患有慢性感染。随着PlantPharm的专利技术，生产成本B型肝炎疫苗，每剂费用降低到受助人近50％。剂量也口头而不是注射，使其更容易在质量与数量，管理比液体疫苗，在制冷不足和基础设施的限制，如在第三世界国家，地方的特殊问题更大的货架寿命。

来源：
PlantPharm生物医学

MP4

www.hbvhbv.com/forum/thread-65071-1-1.html

StephenW

MP4 发表于 2011-4-6 19:32
www.hbvhbv.com/forum/thread-65071-1-1.html

澳大利亚将使用香蕉.